Hikma Pharmaceuticals (CHIX:HIKL) Other Long-Term Liabilities : £143 Mil (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Hikma Pharmaceuticals Other Long-Term Liabilities?

Hikma Pharmaceuticals's other long-term liabilities for the quarter that ended in Dec. 2024 was £143 Mil.

Hikma Pharmaceuticals's quarterly other long-term liabilities increased from Dec. 2023 (£81 Mil) to Jun. 2024 (£83 Mil) and increased from Jun. 2024 (£83 Mil) to Dec. 2024 (£143 Mil).

Hikma Pharmaceuticals's annual other long-term liabilities declined from Dec. 2022 (£91 Mil) to Dec. 2023 (£81 Mil) but then increased from Dec. 2023 (£81 Mil) to Dec. 2024 (£143 Mil).

Hikma Pharmaceuticals Other Long-Term Liabilities Historical Data

The historical data trend for Hikma Pharmaceuticals's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Other Long-Term Liabilities Chart

Hikma Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Long-Term Liabilities

Get a 7-Day Free Trial

145.08

123.33

91.13

80.58

143.17

Hikma Pharmaceuticals Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Long-Term Liabilities	Get a 7-Day Free Trial															91.13	87.91	80.58	83.32	143.17

Hikma Pharmaceuticals Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Hikma Pharmaceuticals Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Hikma Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (CHIX:HIKl) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

HKMPY:USA HKMPF:USA HIK:UK H5P:Germany

Address

1 New Burlington Place, London, GBR, W1S 2HR

Website

https://www.hikma.com

Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.

Hikma Pharmaceuticals Headlines

No Headlines